Core Viewpoint - Meiz Health (02415) reported a mid-year performance for 2025, showing significant growth in both revenue and net profit, driven by the recovery in the pharmaceutical industry and the shift towards evidence-driven marketing models in domestic pharmaceutical companies [1] Financial Performance - Revenue reached 125 million RMB, representing a year-on-year increase of 13.2% [1] - Net profit amounted to 13.239 million RMB, reflecting a remarkable year-on-year growth of 5238.3% [1] - Basic earnings per share were 2.45 cents, with an interim dividend proposed at 1.1 Hong Kong cents per share [1] Industry Trends - The increase in total revenue is primarily attributed to the recovery in the pharmaceutical sector [1] - There is a growing demand for precision omnichannel marketing solutions, driven by the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models [1]
梅斯健康发布中期业绩，净利润1323.9万元，同比增长5238.3%